Trial Profile
Immunotherapy With CD19/22 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ and/or CD22+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Obecabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Burkitt's lymphoma; Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CARPALL
- 13 Dec 2022 Results(n=12) assessing safety and biological efficacy of AUTO1/22 in a Phase I study in children young adults with relapsed and refractory Acute Lymphoblastic Leukaemia presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2022 According to an Autolus media release, data from the trial will be presented at the American Society of Hematology (ASH) Annual Meeting 2022.
- 17 Jun 2022 Results (n=10) assessing safety and biological efficacy of AUTO1/22 in relapsed/refractory acute lymphoblastic leukaemia, presented at the 27th Congress of the European Haematology Association.